Programs

  • Program 1 [2020]

    PATIENT PROGRAM SERVICES/ RESEARCH SERVICES OF WHICH 50,000 BY ICAN'S MULTISTAKEHOLDER EXON 20 GROUP IS A GRANT TO THE BROAD INSTITUTE AT MIT AND HARVARD. ICAN FOCUSES ON PATIENT RESEARCH IN HEMATOLOGICAL, SOLID TUMOR, SYNCHRONOUS CANCERS, AND RARE CANCERS (INCLUDING RARE LUNG CANCERS) AS WELL AS PATIENT ACCESS ISSUES (INCLUDING COMPASSIONATE USE), CLINICAL TRIAL DESIGN AND PROTOCOL REVIEW, MITIGATION OF TREATMENT-RELATED SIDE EFFECTS FROM DRUGS IN TRIALS OR IN THE STANDARD ARMAMENTARIUM.
    Geographies
    Not indicated
    Dates
    Jan 1, 2020 – Dec 31, 2020
    Source
    990
    No causes provided
    No populations provided
    –
    $367.2K

  • Program 2 [2020]

    PATIENT EDUCATION/PATIENT ACCESS SERVICES--FOCUSING ON PRECISION MEDICINE, HEALTH EQUITY ISSUES, HEALTH INFORMATION TECHNOLOGY PROJECTS, AND IMPROVING PATIENT ACCESS TO DETECT AND TREAT CANCER AT ITS EARLIEST STAGES (PARTICULARLY MOLECULAR DIAGNOSTICS AND IMAGING)
    Geographies
    Not indicated
    Dates
    Jan 1, 2020 – Dec 31, 2020
    Source
    990
    No causes provided
    No populations provided
    –
    $121K

  • Program 3 [2020]

    MOLECULAR PROFILING/CLINICAL TRIALS MATCHING SERVICES--ADVISING PATIENTS ON THE IMPORTANCE OF MOLECULAR PROFILING (GENOMICS, PROTEOMICS, TRANSCRIPTOMICS, AND IMMUNE CELL STUDIES;) REVIEWING PROFILING REPORTS WITH PATIENTS, CARE PARTNERS, AND MEMBERS OF ICAN'S PROFESSIONAL COUNCILS; AND CONNECTING PATIENTS TO PRINCIPAL INVESTIGATORS AND STUDY TEAMS ON A PAN- TUMOR/PAN-HEME/PAN-RARE CANCER BASIS.
    Geographies
    Not indicated
    Dates
    Jan 1, 2020 – Dec 31, 2020
    Source
    990
    No causes provided
    No populations provided
    –
    $81K